GC Biopharma's licensed flu vaccine gets approval in Taiwan

South Korea's pharmaceutical firm GC Biopharma Corp. announced on Monday that its quadrivalent flu vaccine has received marketing approval from the Taiwanese Food and Drug Administration within the Ministry of Health and Welfare.

The company licensed the vaccine to Medigen Vaccine Biologics Corporation, a pharmaceutical company based in Taiwan, as part of their technology transfer partnership signed in 2018.

As per the licensing agreement, GC Biopharma will supply Medigen with the flu vaccine stock solution, while Medigen will use the transferred vaccine manufacturing technology to establish a local production system.

GC Biopharma aims to use the Taiwanese market as a stepping stone to accelerate the localization of vaccine production and build a global vaccine infrastructure based on their strong vaccine technology accumulated over half a century, according to Huh Eun-chul, CEO of GC Biopharma.

Write to Jeong Min Nam at peux@hankyung.com